Victory Capital Management Inc. Has $1.38 Million Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Victory Capital Management Inc. increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 11.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 113,630 shares of the company’s stock after buying an additional 11,216 shares during the quarter. Victory Capital Management Inc.’s holdings in Elanco Animal Health were worth $1,376,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health in the third quarter valued at $35,000. Jones Financial Companies Lllp raised its holdings in shares of Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after acquiring an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. lifted its position in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after acquiring an additional 3,411 shares in the last quarter. Blue Trust Inc. boosted its stake in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after purchasing an additional 1,894 shares during the last quarter. Finally, Spire Wealth Management increased its holdings in Elanco Animal Health by 107.4% during the 4th quarter. Spire Wealth Management now owns 7,776 shares of the company’s stock worth $94,000 after purchasing an additional 4,026 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Transactions at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $10.82 on Wednesday. Elanco Animal Health Incorporated has a twelve month low of $10.03 and a twelve month high of $18.80. The stock’s 50 day moving average price is $11.41 and its 200-day moving average price is $12.67. The company has a market capitalization of $5.35 billion, a PE ratio of 27.04, a PEG ratio of 2.50 and a beta of 1.44. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the firm earned $0.08 EPS. Elanco Animal Health’s quarterly revenue was down 1.4% on a year-over-year basis. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ELAN shares. Barclays dropped their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Piper Sandler lowered their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.